Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2024-04-26 | Orexo | Report from Orexo AB's annual general meeting, 26 April 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-26 | Orexo | Kommuniké från Orexo AB:s årsstämma den 26 april 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-25 | Penser Access by Carnegie | Penser Access by Carnegie: Orexo - Valutavinden har vänt, effekten begränsad i Q1 | Pressreleaser | Visa Stäng |
|
||||
2024-04-17 | Orexo | Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-17 | Orexo | Orexo förstärker patentskyddet i USA för OX640, ett pulverbaserat nasalt adrenalinläkemedel | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-02 | Orexo | Orexo announces that the condition for early redemption of its existing bonds has been fulfilled | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Orexo announces that the condition for early redemption of its existing bonds has been fulfilledThe early redemption was conditional upon that settlement of the Company’s issue of new senior secured social bonds with a tenor of four years has occurred, which is further described in the Company’s press release on March 13, 2024. This condition has been fulfilled and the early redemption is therefore no longer conditional. Hence, the early redemption will occur on April 11, 2024, and the redemption amount will be paid to each person who is registered as owner of Existing Bonds in the debt register maintained by Euroclear Sweden at the end of business on April 4, 2024. For further information on the early redemption, see the Company’s press release on March 13, 2024, and the notice of early redemption which is available on the Company’s website. For further information please contact: Nikolaj Sørensen, President and CEO Fredrik Järrsten, EVP and CFO Lena Wange, IR & Communications Director Tel: +46 (0)18780 88 00 E-mail: About Orexo Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo is listed on Nasdaq Stockholm’s main list and is available as an ADR on OTCQX (ORXOY) in the US. For more information about Orexo please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube. The information was sent for publication, through the agency of the contact person set out above, on April 2, 2024, at 1.15 pm CET. |
||||
2024-04-02 | Orexo | Orexo meddelar att villkoret för förtida inlösen av sina befintliga obligationer har uppfyllts | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-28 | Orexo | Orexo publicerar års- och hållbarhetsredovisning för 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-03-28 | Orexo | Orexo publishes the Annual and Sustainability Report for 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-03-21 | Penser Access by Carnegie | Penser Access by Carnegie: Orexo - Stärka finanser | Pressreleaser | Visa Stäng |
|
||||
2024-03-15 | Orexo | Correction: Notice of Annual General Meeting of Orexo | Pressreleaser | Visa Stäng |
|
||||
2024-03-15 | Orexo | Rättelse: Kallelse till årsstämma i Orexo | Pressreleaser | Visa Stäng |
|
||||
2024-03-15 | Orexo | Notice of Annual General Meeting of Orexo | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-15 | Orexo | Kallelse till årsstämma i Orexo | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-13 | Orexo | Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-13 | Orexo | Orexo har framgångsrikt emitterat seniora säkerställda sociala obligationer med rörlig ränta om SEK 500 m och offentliggör resultatet av återköpserbjudandet avseende sina befintliga obligationer | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-08 | Orexo | Orexo överväger emission av seniora säkerställda sociala obligationer med rörlig ränta och offentliggör villkorat återköpserbjudande avseende sina befintliga obligationer | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-08 | Orexo | Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-08 | Orexo | Orexo strengthens its sustainability work by establishing a social financing framework | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-08 | Orexo | Orexo stärker sitt hållbarhetsarbete genom att etablera ett socialt finansieringsramverk | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-12 | Orexo | Orexo and Sobi agree to advance feasibility study with AmorphOX | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-12 | Orexo | Orexo och Sobi avancerar förstudie med AmorphOX | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-08 | Orexo | Orexo delårsrapport kv 4 2023, inkl. bokslutskommuniké | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-08 | Orexo | Orexo Interim Report Q4 2023, incl. Full Year Report | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-06 | Orexo | Orexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-06 | Orexo | Orexos studieresultat för OX640 presenteras vid AAAAI:s Annual Meeting 2024 i Washington, DC, USA | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-01 | Penser Access by Carnegie | Penser Access by Carnegie: Orexo - Motvind från valutan | Pressreleaser | Visa Stäng |
|
||||
2023-11-29 | Penser Access | Penser Access: Interview with Orexo - Erik Penser Bank - Nov 29th 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-11-28 | Orexo | Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-28 | Orexo | Orexo meddelar att FDA accepterat registreringsansökan för granskning av OX124, ett högdosläkemedel vid opioidöverdos | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-06 | Penser Access | Penser Access: Intervju med Orexo - Erik Penser Bank - 6 november 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-11-03 | Penser Access | Penser Access: Går mot lönsamhet, men tillväxten dröjer - Orexo | Pressreleaser | Visa Stäng |
|
||||
2023-11-02 | Orexo | Orexo Q3 2023 Interim Report | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-02 | Orexo | Orexo delårsrapport kv 3 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-10-27 | Orexo | Orexo meddelar förändringar i styrelsen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-27 | Orexo | Orexo announces changes in the company's Board of Directors | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-26 | Orexo | Orexo:s valberedning inför årsstämman 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-26 | Orexo | Orexo's Nomination Committee for the Annual General Meeting 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-26 | Orexo | Kommuniké från Orexo:s extra bolagsstämma | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-26 | Orexo | Report from Orexo's extraordinary general meeting | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-11 | Orexo | Orexo announces data from the MODIA® study evaluating impact on use of illicit opioids | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-11 | Orexo | Orexo offentliggör data från MODIA-studien som utvärderar effekten på användning av otillåtna opioider | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-02 | Orexo | Kallelse till extra bolagsstämma i Orexo AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-02 | Orexo | Notice of Extraordinary General Meeting in Orexo AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-02 | Penser Access | Penser Access: Intervju med Orexo - Erik Penser Bank - 2 oktober 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-09-27 | Orexo | BioStock Investor Meeting: Orexo | Pressreleaser | Visa Stäng |
|
||||
2023-09-27 | Orexo | BioStock Investor Meeting: Orexo | Pressreleaser | Visa Stäng |
|
||||
2023-09-18 | Orexo | Orexo lämnar in registreringsansökan till FDA för OX124, ett högdos-läkemedel vid opioidöverdos | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-18 | Orexo | Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-05 | Orexo | Orexo deltar i Pareto Securities 14[th] Annual Healthcare Conference 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-05 | Orexo | Orexo to participate in Pareto Securities' 14[th] Annual Healthcare Conference 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-29 | Orexo | Orexo säkrar patentskydd i USA för OX640, ett pulverbaserat nasalt adrenalinläkemedel | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-29 | Orexo | Orexo secures patent protection in the US for OX640, a nasal epinephrine powder product | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-24 | Orexo | Orexo's patent win for ZUBSOLV[®] appealed | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-24 | Orexo | Orexo:s seger i patenttvisten för ZUBSOLV[®] överklagas | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-20 | Penser Access | Penser Access: Det har vänt, men värderingen släpar - Orexo | Pressreleaser | Visa Stäng |
|
||||
2023-07-19 | Penser Access | Penser Access: Intervju med Orexo - Erik Penser Bank - 19 juli 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-07-18 | Orexo | Orexo delårsrapport kv 2 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-07-18 | Orexo | Orexo Q2 2023 Interim Report | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-07-03 | Penser Access | Penser Access: Intervju med Orexo - Erik Penser Bank - 3 juli 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-07-03 | Penser Access | Penser Access: Segrar i patenttvist - Orexo | Pressreleaser | Visa Stäng |
|
||||
2023-07-01 | Orexo | Orexo wins patent litigation for ZUBSOLV® in the US | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-01 | Orexo | Orexo vinner patenttvist för ZUBSOLV® i USA | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-22 | Penser Access | Penser Access: Krisvärdering inför viktiga besked - Orexo | Pressreleaser | Visa Stäng |
|